mRNA vaccines are our best bet at addressing viral persistence. They can prevent infection as well as improve responses against infection. They are also faster, cheaper, and more flexible to make than their traditional counterparts. mRNA vaccines are like injectable instructions that turn a body's cells into factories that can create any protein for which mRNA instructions can be built. This means they can be used to teach the body to mount an immune response to any target foreign protein - including proteins on cancer cells.

Iloprost, a drug that can prevent the need to amputate frozen fingers and toes due to frostbite, has been approved as a treatment for frostbite by the FDA. The drug has already been used to treat frostbite for years in a number of European countries and elsewhere in the world. It works as a vasodilator, widening blood vessels and improving blood flow. Iloprost prevents blood clotting and is also used to treat blood pressure-related illnesses.

Tarsus Pharmaceuticals is developing a pill that could provide protection against Lyme disease for several weeks at a time. An early-stage trial has shown that it can kill ticks on people for up to 30 days after 24 hours of ingestion. The drug only kills the ticks, rather than the bacteria that causes Lyme disease. It may also protect against other tick-borne diseases.

Scientists from the University of Amsterdam claim they have successfully eliminated HIV from infected cells using CRISPR gene-editing technology. The work remains a proof-of-concept and will not become a cure for the disease any time soon. The study's findings are still being scrutinized.

Researchers have used a generative AI tool called RFdiffusion to make completely new antibodies for the first time. The proof-of-principle work paves the way for the design of antibody drugs at the touch of a button. The technology is still a long way from reaching the clinic.

A new experimental treatment developed by biotechnology firm LyGenesis may lead to patients growing an additional miniature liver. The approach involves injecting healthy liver cells into a lymph node in the upper abdomen of a patient with liver failure. The cells multiply and take over the lymph node to form a structure that can perform a liver's blood-filtering duties. The first person who received the treatment (on March 25) is recovering well, but they will need to be closely monitored for a while to see if the treatment is both safe and effective. The treatment has worked so far in mice, dogs, and pigs.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Engineers from the University of New South Wales in Australia are working on a prototype solar panel implant for the retinas to restore sight. The implant converts light into electrical signals that can be directed to the optic nerve, enabling vision. Users may need to wear special glasses or goggles that amplify sunlight for the device to work. The device is still in a proof-of-concept stage - a lot more work still needs to be done before it is ready for human implantation.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Engineers from the University of New South Wales in Australia are working on a prototype solar panel implant for the retinas to restore sight. The implant converts light into electrical signals that can be directed to the optic nerve, enabling vision. Users may need to wear special glasses or goggles that amplify sunlight for the device to work. The device is still in a proof-of-concept stage - a lot more work still needs to be done before it is ready for human implantation.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Engineers from the University of New South Wales in Australia are working on a prototype solar panel implant for the retinas to restore sight. The implant converts light into electrical signals that can be directed to the optic nerve, enabling vision. Users may need to wear special glasses or goggles that amplify sunlight for the device to work. The device is still in a proof-of-concept stage - a lot more work still needs to be done before it is ready for human implantation.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Engineers from the University of New South Wales in Australia are working on a prototype solar panel implant for the retinas to restore sight. The implant converts light into electrical signals that can be directed to the optic nerve, enabling vision. Users may need to wear special glasses or goggles that amplify sunlight for the device to work. The device is still in a proof-of-concept stage - a lot more work still needs to be done before it is ready for human implantation.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Engineers from the University of New South Wales in Australia are working on a prototype solar panel implant for the retinas to restore sight. The implant converts light into electrical signals that can be directed to the optic nerve, enabling vision. Users may need to wear special glasses or goggles that amplify sunlight for the device to work. The device is still in a proof-of-concept stage - a lot more work still needs to be done before it is ready for human implantation.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Engineers from the University of New South Wales in Australia are working on a prototype solar panel implant for the retinas to restore sight. The implant converts light into electrical signals that can be directed to the optic nerve, enabling vision. Users may need to wear special glasses or goggles that amplify sunlight for the device to work. The device is still in a proof-of-concept stage - a lot more work still needs to be done before it is ready for human implantation.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Engineers from the University of New South Wales in Australia are working on a prototype solar panel implant for the retinas to restore sight. The implant converts light into electrical signals that can be directed to the optic nerve, enabling vision. Users may need to wear special glasses or goggles that amplify sunlight for the device to work. The device is still in a proof-of-concept stage - a lot more work still needs to be done before it is ready for human implantation.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Engineers from the University of New South Wales in Australia are working on a prototype solar panel implant for the retinas to restore sight. The implant converts light into electrical signals that can be directed to the optic nerve, enabling vision. Users may need to wear special glasses or goggles that amplify sunlight for the device to work. The device is still in a proof-of-concept stage - a lot more work still needs to be done before it is ready for human implantation.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Engineers from the University of New South Wales in Australia are working on a prototype solar panel implant for the retinas to restore sight. The implant converts light into electrical signals that can be directed to the optic nerve, enabling vision. Users may need to wear special glasses or goggles that amplify sunlight for the device to work. The device is still in a proof-of-concept stage - a lot more work still needs to be done before it is ready for human implantation.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Engineers from the University of New South Wales in Australia are working on a prototype solar panel implant for the retinas to restore sight. The implant converts light into electrical signals that can be directed to the optic nerve, enabling vision. Users may need to wear special glasses or goggles that amplify sunlight for the device to work. The device is still in a proof-of-concept stage - a lot more work still needs to be done before it is ready for human implantation.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Engineers from the University of New South Wales in Australia are working on a prototype solar panel implant for the retinas to restore sight. The implant converts light into electrical signals that can be directed to the optic nerve, enabling vision. Users may need to wear special glasses or goggles that amplify sunlight for the device to work. The device is still in a proof-of-concept stage - a lot more work still needs to be done before it is ready for human implantation.

Novo Nordisk's new obesity treatment drug, amycretin, helped patients lose 13% of their body weight in just 12 weeks. The drug may be more effective than semaglutide. Amycretin targets GLP-1 and another hormone called amylin, both of which are believed to be linked to hunger and satiety. The drug still needs to go through much larger trials that will likely drag on for years before it will be publicly available. The results of the initial trials sent Novo Nordisk's stock rising as much as 8.3%.

Engineers from the University of New South Wales in Australia are working on a prototype solar panel implant for the retinas to restore sight. The implant converts light into electrical signals that can be directed to the optic nerve, enabling vision. Users may need to wear special glasses or goggles that amplify sunlight for the device to work. The device is still in a proof-of-concept stage - a lot more work still needs to be done before it is ready for human implantation.